A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
09/06/2021at 15:09

Hearing company enters into first partnership in big venture in India

Shortly after Audientes launched a new subsidiary in India, the hearing company is ready to enter its first partnership agreement with a hearing center in the country, which represents the largest global market for the company's target group.
Steen Thygesen, CEO, Audientes | Photo: Audientes / PR
BY ALBERT RØNNING ANDERSSON, TRANSLATED BY CATHERINE BRETT

Audientes, which specializes in selling cheap hearing aids to low-income countries, has entered into a partnership with Hearing Wellness Clinic (HWC), which is a chain of hearing centers in South India. From July, Audientes' self-adjusting devices will be sold at their 20 clinics.

This partnership comes shortly after Audientes launched a subsidiary company in Hyderabad, which is the sixth largest Indian city, with 10.2 million inhabitants.

The company in Hyderabad is the first of many future subsidiaries in India, and will be at the center of the commercialization of Audientes' hearing aid. According to the company, the price tag of USD 350 does not put the product out of reach of even the least-wealthy Indians.

"Ahead of the introduction of our self-adjusting hearing aid onto the Indian market, and in line with our strategy and roll-outs in the country, we have entered into an incredibly exciting partnership with Hearing Wellness Clinic, which is one of the leading hearing centers in Southern India within the sale and advice relating to high-quality hearing aids," says Steen Thygesen, CEO of Audientes, to MedWatch.

The agreement with HWC is a manifestation of the potential of our product concept within established hearing aid sales channels, where Audientes' products adress an unmet need

Steen Thygesen, CEO of Audientes

It is estimated that in India alone, over 75 million people live with dehabilitating hearing loss. Audientes aims to create a broad, country-wide sales platform in India, with departments in Delhi, Mumbai, Bengaluru and Kolkata. It will target the growing middle class, which encompasses around 300 million consumers spread across major cities.

Increasing partner's client segment

Thygesen says that Hearing Wellness Clinic has 15 years of experience in selling high quality, optimal hearing solutions, and that their presence in over 20 locations across a number of cities makes them the perfect partner.

"The agreement with HWC is a manifestation of the potential of our product concept within established hearing aid sales channels, where Audientes' products adress an unmet need on the market," Thygesen says, suggesting the commercial potential is also significant.

"HWC is one of the biggest hearing aid chains in India, a market that is quite fragmented when it comes to retail. We will now collaborate with HWC in our efforts to reach as many users as possible, just like we expect to from similar partnerships elsewhere to to reach the most densely populated areas of the country."

Hearing Wellness Clinic is among the 10 biggest providers of hearing aids in India, and although they traditionally sell more expensive products, there is increasing demand for options on the cheaper end of the scale, which also require less support from stores to maintain.

"In other words, products with less complexity and that are faster to set up, which is very relevant to our self-adjusting product, with good quality at a good price. With our hearing aid, HWC can serve the customers they would otherwise have sent away to competitors or to find other solutions," says Thygesen.

Hearing Wellness Clinic also sells products from other brands, including Oticon, Demant's Sonic Innovations, Sonova's Phonak and Unitron, Siemens and Starkey, it states on its website.

Building bridges between online and clinical sales

Audientes, which was established in 2014, has a declared goal of working against the hearing industry dogma of high prices and the need for audiologists and regular adjustments at hearing clinics.

The company aims to achieve this through the use of wholesale channels, retail chains and direct sales to consumers through online sales. India is the world's second-largest e-trading market.

Measured by retail sales alone, India is the world's eighth-largest e-trading market, and online retail sales are expected to grow by around 30 percent annually over the next five years.

The significant shift in Indian online shopping has also led to a noteworthy rise within the e-healthcare industry, which is expected to be worth USD 16m in 2025, Thygesen reports.

"Alongside HWC, we will work intensively to introduce the product on the Indian market from Q3 this year. But we will also work together to build bridges between traditional sales at hearing clinics and e-commerce," he says.

The agreement with HWC is a manifestation of the potential of our product concept within established hearing aid sales channels, where Audientes' products adress an unmet need

Steen Thygesen, CEO of Audientes

Related articles:

  • Audientes CEO Steen Thygesen | Photo: Audientes / PR

    Audientes builds up momentum and prepares for Q3 launch

    For subscribers

  • Photo: WS Audiology/PR

    WS Audiology joins Science Based Targets initiative

    For subscribers

  • Demant CFO René Schneider and CEO Søren Nielsen | Photo: Demant / PR

    Demant and GN ramp up investments – with money to spare

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

When GN Group’s chair retires following the company’s next AGM, it could pave the way for a large consolidation within the Danish hearing aid market, an analyst says.

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking. 

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Experienced Patent Counsel

  • Lead Data Architect

  • Head of Regulatory Affairs Danmark

  • Commercial Director

  • Application Manager

  • Clinical Operational Associate

  • Principal Laboratory Technologist

  • Application Manager

  • Head of International Sales

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

See all jobs

Jobs

  • Experienced Patent Counsel

  • Lead Data Architect

  • Head of Regulatory Affairs Danmark

  • Commercial Director

  • Application Manager

  • Clinical Operational Associate

  • Principal Laboratory Technologist

  • Application Manager

  • Head of International Sales

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Senior Regulatory Affairs Professional

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge